ABLYNX Announces Second Extension of its NANOBODY® Drug Discovery and Development Alliance - Gilde Healthcare

ABLYNX Announces Second Extension of its NANOBODY® Drug Discovery and Development Alliance

February 5, 2009

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its drug discovery and development alliance with Novartis has been extended for another year.

Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel Nanobody®-based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments. Novartis has exclusive rights to develop and commercialise the Nanobody® products resulting from the collaboration.

This agreement was previously extended in December 2007 and, based on the positive progress made, the companies have mutually agreed to extend their alliance for another year.

As part of the collaboration Ablynx receives license fees and funding for research and development. In addition, Ablynx is eligible for milestone payments and royalties upon commercialisation.

Edwin Moses, CEO and Chairman of Ablynx, commented:

“We are very pleased with our collaboration with Novartis, one of the leading pharmaceutical companies with a significant track record in innovative drug development, and we look forward to continuing to work together with the goal to advance Nanobody®-based programmes into the clinic.”

ends

About Ablynx [Euronext Brussels: ABLX]www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 200 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Nanobodies® have been generated against more than 100 different disease targets. Importantly the Nanobodies® which naturally exist in llamas have a very high homology with humans.

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
February 29, 2024

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent...
February 28, 2024

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125...
February 27, 2024